|
Phase II clinical trial for the evaluation of the therapeutic vaccine candidate Terap C. |
2009-02-11 |
CIGB |
|
THERESA-3 Study |
2009-12-11 |
CIGB |
|
Phase I/II clinical trial for the evaluation of vaccine candidate CIGB-230 in patients with chronic renal insufficiency. |
2010-09-27 |
CIGB |
|
Interferon Combination in basal cell carcinoma (InCarbacel-IV study) |
22/08/2013 |
CIGB |
|
ESPERANZA study |
14/04/2020 |
CIGB |
|
THERESA-5 Study |
08/04/2015 |
CIGB |
|
CIGB 2020 in contacts and SARS-CoV-2 infection suspects |
13/04/2020 |
CIGB |
|
VIDA study |
22/06/2020 |
CIGB |
|
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. |
2010-12-28 |
CIM |
|
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. |
2010-12-29 |
CIM |
|
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. |
2010-12-29 |
CIM |
|
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. |
2010-12-29 |
CIM |
|
99mTc-marked 14F7 MaB in metastatic breast, phase II |
2008-12-27 |
CIM |
|
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II |
2010-12-17 |
CIM |
|
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. |
2010-12-17 |
CIM |
|
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab |
12/05/2020 |
CIM |
|
NGcGM3/VSSP in small cell lung cancer |
07/12/2016 |
CIM |
|
NGcGM3/VSSP in Metastatic melanoma |
07/12/2016 |
CIM |
|
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
05/11/2013 |
CIM |
|
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. |
23/05/2014 |
CIM |
